spacer
home > ebr > spring 2004 > patently better - the rights and wrongs of patent protection drug discovery technology
PUBLICATIONS
European Biopharmaceutical Review

Patently Better - The Rights and Wrongs of Patent Protection Drug Discovery Technology

Whether to secure development funding, protect product licence fees or simply to stop third parties profiting from the fruits of their research, the patent is an essential business tool for firms in the biopharmaceutical field. This article looks at the essential role that patents play, and explores some important recent changes affecting the availability of patent protection.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gareth Williams is a Patent Attorney and European Trade Mark Attorney at Marks and Clerk. Gareth obtained an honours degree in Biological Sciences from Oxford University, where he remained to complete a doctorate in Molecular Biology and Genetics researching the Y chromosome, funded as part of the Human Genome Project. He entered the patent profession in 1998 and is a qualified UK and European Patent Attorney. He has acted for clients in a variety of fields, but specialises particularly in patent work in the fields of biotechnology, medical devices, business method inventions and mechanical devices. His practice involves the drafting, filing and prosecution of patent applications worldwide, the handling of opposition and appeal work at the European Patent Office, and advice on infringement matters and general intellectual property strategy.

spacer
Gareth Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches Next-Generation Technology for Advanced Live Cell Imaging


More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 
Industry Events

BIO-Europe Spring® 2017

20-22 March 2017,

BIO-Europe Spring®is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement